news
Insilico and Qilu partner to create generative AI cardiometabolic drugs
Insilico Medicine and Qilu Pharmaceutical Group are expanding their existing R&D collaboration to apply generative AI to cardiometabolic drug discovery.
List view / Grid view
Obesity
news
Beige fat identified as potential target for blood pressure drugs
New research shows beige fat around blood vessels helps regulate blood pressure, offering potential pathways for future therapies to reduce cardiovascular risk.
news
TRPM5 protein switch discovery could lead to new diabetes drugs
Northwestern University scientists have discovered a hidden ‘control switch’ in the TRPM5 protein, which helps regulate taste, blood sugar and gut health and could lead to new therapies for targeting diabetes and obesity.
article
The future of obesity drugs starts in preclinical discovery
Progress in preclinical models and biomarker science is improving early-stage obesity drug development. This article outlines the emerging targets and technologies behind this shift.
news
Estrone hormone linked to deadly breast cancer in obese women
A new analysis has identified the hormone estrone as a major driver of aggressive breast cancer in post-menopausal women with obesity, meaning that weight-loss drugs could help improve treatment outcomes.
news
AI powers discovery of new CBLB inhibitor ISM3830
Insilico Medicine has announced ISM3830, an AI-designed CBLB inhibitor that has demonstrated promising preclinical results.
news
GLP-1 weight loss drugs may protect against pancreatitis
A new study has found that GLP-1 weight loss drugs do not increase the risk of pancreatitis or heart problems in patients with high triglycerides – and may even help protect against the condition.
article
Beyond weight loss: the gap in current drug development for obesity
Current obesity drug development remains overly focused on short-term weight reduction, despite obesity being a chronic, multifactorial disease. Broader, mechanism-driven approaches are needed to ensure durable efficacy, safety and accessibility.
news
TRF1 protein identified as potential obesity drug target
Researchers have discovered that removing a telomere-protecting protein, TRF1, makes mice leaner and metabolically healthier without shortening their telomeres, potentially leading to new methods for tackling obesity and age-related diseases.
news
New compound blend reverses sugar damage to tackle ageing and obesity
Scientists have developed a compound blend that reverses sugar-related cellular damage in mice, which could lead to future therapies to slow ageing and treat metabolic diseases.
news
Enzyme PapB could boost diabetes and obesity peptide drugs
Researchers have discovered an enzyme, PapB, that can ‘tie off’ therapeutic peptides into stable rings, which could help improve GLP-1 drugs for diabetes and obesity – making them more effective and longer lasting.
news
New obesity drug RES-010 targets metabolism to prevent weight regain
A first-in-class obesity drug, presented at the European Association for the Study of Diabetes meeting in Vienna, aims to reprogramme metabolism rather than suppress appetite – offering the potential for long-lasting weight loss without regain.
news
New imaging technique tracks obesity drug tirzepatide in cells
Scientists have developed fluorescent probes that reveal how dual agonist drugs like tirzepatide target cells in the pancreas and brain, offering new insights into diabetes and obesity treatments.
news
New data backs Myo4 for obesity treatment
MitoRx Therapeutics has announced new preclinical data for its small molecule Myo4, showing restored insulin sensitivity and enhanced fat loss with muscle preservation in an obesity model - offering a potential alternative to GLP-1-based therapies.
news
FGF19 hormone could be the key to new obesity treatments
A hormone produced in the gut, FGF19, has been shown to act directly on the brain to boost energy expenditure, burn fat and improve blood sugar control in obese mice - offering a potential route for developing new obesity therapies.
